While the collective evidence supporting MEK-SHP2 dual inhibition in KRAS-driven tumours is overwhelming, it is clear that this combination also works in additional tumour contexts, including those driven by ERK signalling either via BRAF mutations, overexpressed RTKs, or even under wild-type KRAS background[33-37]. The gene discussed is KRAS; the disease is neoplasm.